Management of type 2 diabetes in 2017 getting to goal

JAMA - Journal of the American Medical Association

Volumn 317, Issue 10, 2017, Pages 1015-1016

  Reusch, Jane E B ^a,b   Manson, Jo Ann E ^c,d  

^a UNIVERSITY OF COLORADO   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; HEMOGLOBIN A1C; INCRETIN; INSULIN; METFORMIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; SODIUM GLUCOSE COTRANSPORTER 2;

BEHAVIOR CHANGE; BLOOD GLUCOSE MONITORING; COMBINATION DRUG THERAPY; DIABETES EDUCATION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; LIFESTYLE MODIFICATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PATIENT PARTICIPATION; PATIENT SAFETY; PRACTICE GUIDELINE; REVIEW; SELF CARE; ANTAGONISTS AND INHIBITORS; BLOOD; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GLUCOSE BLOOD LEVEL; HEALTHY LIFESTYLE; HYPERGLYCEMIA; METABOLISM; MOTIVATION; MULTIMODALITY CANCER THERAPY;

BLOOD GLUCOSE; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; GOALS; HEALTHY LIFESTYLE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INCRETINS; INSULIN; METFORMIN; PATIENT-CENTERED CARE; SODIUM-GLUCOSE TRANSPORTER 2;

EID: 85015871607     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2017.0241     Document Type: Review

References (9)

1. US Centers for Disease Control and Prevention. Diabetes statistics. http://www.cdc.gov/diabetes/data/statistics/2014statisticsreport.html. Accessed January 4, 2017
2. American Diabetes Association. Diabetes statistics. http://www.diabetes.org. Accessed January 4, 2017
3. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes, 2015. Diabetes Care. 2015;38(1):140-149
4. Sherr D, Lipman RD. The diabetes educator and the diabetes self-management education engagement. Diabetes Educ. 2015;41(5):616-624
5. Holden SE, Jenkins-Jones S, Currie CJ. Association between insulin monotherapy versus insulin plus metformin and the risk of all-cause mortality and other serious outcomes. PLoS One. 2016;11(5):e0153594
6. Garber AJ, Abrahamson MJ, Barzilay JI, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm-2016 executive summary. Endocr Pract. 2016;22(1):84-113
7. Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311-322
8. Marso SP, Bain SC, Consoli A, et al; SUSTAIN-6 Investigators. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834-1844
9. Zinman B, Wanner C, Lachin JM, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128